Next Article in Journal
Mutations in bdcA and valS Correlate with Quinolone Resistance in Wastewater Escherichia coli
Next Article in Special Issue
Computational Methods to Study Human Transcript Variants in COVID-19 Infected Lung Cancer Cells
Previous Article in Journal
3′ Tth Endonuclease Cleavage Polymerase Chain Reaction (3TEC-PCR) Technology for Single-Base-Specific Multiplex Pathogen Detection using a Two-Oligonucleotide System
Previous Article in Special Issue
Rapidly Growing Protein-Centric Technologies to Extensively Identify Protein–RNA Interactions: Application to the Analysis of Co-Transcriptional RNA Processing

Minor Intron Splicing from Basic Science to Disease

Weill Cornell Medicine-Qatar, Education City, Doha P.O. Box 24144, Qatar
Biological Sciences Program, Carnegie Mellon University in Qatar, Doha P.O. Box 24866, Qatar
Author to whom correspondence should be addressed.
Academic Editor: Daisuke Kaida
Int. J. Mol. Sci. 2021, 22(11), 6062;
Received: 1 May 2021 / Revised: 17 May 2021 / Accepted: 18 May 2021 / Published: 4 June 2021
(This article belongs to the Special Issue Splicing Modulators Which Affect Gene Expression)
Pre-mRNA splicing is an essential step in gene expression and is catalyzed by two machineries in eukaryotes: the major (U2 type) and minor (U12 type) spliceosomes. While the majority of introns in humans are U2 type, less than 0.4% are U12 type, also known as minor introns (mi-INTs), and require a specialized spliceosome composed of U11, U12, U4atac, U5, and U6atac snRNPs. The high evolutionary conservation and apparent splicing inefficiency of U12 introns have set them apart from their major counterparts and led to speculations on the purpose for their existence. However, recent studies challenged the simple concept of mi-INTs splicing inefficiency due to low abundance of their spliceosome and confirmed their regulatory role in alternative splicing, significantly impacting the expression of their host genes. Additionally, a growing list of minor spliceosome-associated diseases with tissue-specific pathologies affirmed the importance of minor splicing as a key regulatory pathway, which when deregulated could lead to tissue-specific pathologies due to specific alterations in the expression of some minor-intron-containing genes. Consequently, uncovering how mi-INTs splicing is regulated in a tissue-specific manner would allow for better understanding of disease pathogenesis and pave the way for novel therapies, which we highlight in this review. View Full-Text
Keywords: minor introns; U2 introns; U12 introns; minor spliceosome; RNA splicing; disease minor introns; U2 introns; U12 introns; minor spliceosome; RNA splicing; disease
Show Figures

Figure 1

MDPI and ACS Style

El Marabti, E.; Malek, J.; Younis, I. Minor Intron Splicing from Basic Science to Disease. Int. J. Mol. Sci. 2021, 22, 6062.

AMA Style

El Marabti E, Malek J, Younis I. Minor Intron Splicing from Basic Science to Disease. International Journal of Molecular Sciences. 2021; 22(11):6062.

Chicago/Turabian Style

El Marabti, Ettaib, Joel Malek, and Ihab Younis. 2021. "Minor Intron Splicing from Basic Science to Disease" International Journal of Molecular Sciences 22, no. 11: 6062.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop